MGB Biopharma
Manufacturing · United Kingdom · 11-50 Employees
View Company Info for Free
Overview
Headquarters
Willow House Strathclyde Business Park K...Phone Number
+44 1698464224Website
www.mgb-biopharma.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About MGB Biopharma
MGB Biopharma specializes in developing a new class of anti-infective medicines, particularly antibiotics based on Minor Groove Binder (MGB) compounds. The company focuses on creating small molecules with antibacterial activity against both susceptible and resistant bacteria, addressing the growing issue of antibiotic resistance. Their lead drug candidate, MGB-BP-3, has shown promising results in clinical trials for treating Clostridium difficile infections, indicating potential superiority over existing treatments. MGB Biopharma aims to revolutionize the field of antibacterial therapy with its innovative approach and novel mechanism of action.Explore more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is MGB Biopharma your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Funding: Get notified immidiatlly once MGB Biopharma has new funding data
Earning: See what the market has to say on MGB Biopharma recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at MGB Biopharma
Website visits: Recent activity has been detected on your website
Check if MGB Biopharma has recently received funding, and reach out quickly before it becomes old news!
MGB Biopharma, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if MGB Biopharma had a recent Job posting/layoffs
Check out if MGB Biopharma is spiking on competitors!
Product Launch: Get notified when MGB Biopharma launches new products
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Find VP level buyers at MGB Biopharma
Find 3 more new buyers
Compare Similar Companies to MGB Biopharma
Compare insights from companies similar to MGB Biopharma, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
MGB Biopharma
<$5M
11-50
Private
$7.4M
2009
N/A
Company Profile Activity
Activity Insights
MGB Biopharma is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
MGB Biopharma is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about MGB Biopharma.
MGB Biopharma financials insights
Gather financial insights about MGB Biopharma, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2014
Unspecified
$6.4M
2017
Unspecified
$1M
MGB Biopharma Tech Stack
A closer look at the technologies used by MGB Biopharma
MGB Biopharma News & Media
MGB Biopharma Announces Successful Outcome From Phase II Clinical Study with MGB-BP-3 - a Potential New Gold Standard, First-line Treatment for Clostridium difficile Infection (CDI)
MGB Biopharma, a biopharmaceutical company developing a novel class of anti-infectives, today announces that its Phase II clinical study has met its endpoints of safety, efficacy, and dose selection. The study confirms that MGB-BP-3, an antibacterial, has the potential to become the new gold standard, first-line treatment for CDI.MGB Biopharma Announces Promising Phase IIa Clinical Trial Update for MGB-BP-3, a Novel, Potent Bactericidal Antibiotic Targeting Clostridium difficile-Associated Diarrhoea (CDAD)
GLASGOW, Scotland, Oct. 10, 2019 /PRNewswire/ -- MGB Biopharma, a biopharmaceutical company developing a novel class of anti-infectives to address the major global problem of antibiotic resistance, today announces an update on progress in its Phase IIa clinical study. MGB-BP-3 is a potent...MGB Biopharma Completes Funding Round
MGB Biopharma, a Glasgow, Scotland-based biopharmaceutical company developing a novel class of anti-infectives to address antibiotic resistance, completed its latest funding round of undisclosed amount. The round was led by Archangel Investors with participation from Scottish Investment Bank (the investment arm of Scottish Enterprise, Scotland’s national economic development agency), Barwell and TriCapital Investors. The company […] The post MGB Biopharma Completes Funding Round appeared first o
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding MGB Biopharma
Sign Up For FreeTo access detailed company insights
MGB Biopharma specializes in developing a new class of anti-infective medicines, particularly antibiotics based on Minor Groove Binder (MGB) compounds. The company focuses on creating small molecules with antibacterial activity against both susceptible and resistant bacteria, addressing the growing issue of antibiotic resistance. Their lead drug ca... Read More
